Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study.


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 5 10 2018
medline: 15 5 2020
entrez: 5 10 2018
Statut: ppublish

Résumé

The value of the nosological distinction between non-affective and affective psychosis has frequently been challenged. We aimed to investigate the transdiagnostic dimensional structure and associated characteristics of psychopathology at First Episode Psychosis (FEP). Regardless of diagnostic categories, we expected that positive symptoms occurred more frequently in ethnic minority groups and in more densely populated environments, and that negative symptoms were associated with indices of neurodevelopmental impairment. This study included 2182 FEP individuals recruited across six countries, as part of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study. Symptom ratings were analysed using multidimensional item response modelling in Mplus to estimate five theory-based models of psychosis. We used multiple regression models to examine demographic and context factors associated with symptom dimensions. A bifactor model, composed of one general factor and five specific dimensions of positive, negative, disorganization, manic and depressive symptoms, best-represented associations among ratings of psychotic symptoms. Positive symptoms were more common in ethnic minority groups. Urbanicity was associated with a higher score on the general factor. Men presented with more negative and less depressive symptoms than women. Early age-at-first-contact with psychiatric services was associated with higher scores on negative, disorganized, and manic symptom dimensions. Our results suggest that the bifactor model of psychopathology holds across diagnostic categories of non-affective and affective psychosis at FEP, and demographic and context determinants map onto general and specific symptom dimensions. These findings have implications for tailoring symptom-specific treatments and inform research into the mood-psychosis spectrum.

Sections du résumé

BACKGROUND
The value of the nosological distinction between non-affective and affective psychosis has frequently been challenged. We aimed to investigate the transdiagnostic dimensional structure and associated characteristics of psychopathology at First Episode Psychosis (FEP). Regardless of diagnostic categories, we expected that positive symptoms occurred more frequently in ethnic minority groups and in more densely populated environments, and that negative symptoms were associated with indices of neurodevelopmental impairment.
METHOD
This study included 2182 FEP individuals recruited across six countries, as part of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study. Symptom ratings were analysed using multidimensional item response modelling in Mplus to estimate five theory-based models of psychosis. We used multiple regression models to examine demographic and context factors associated with symptom dimensions.
RESULTS
A bifactor model, composed of one general factor and five specific dimensions of positive, negative, disorganization, manic and depressive symptoms, best-represented associations among ratings of psychotic symptoms. Positive symptoms were more common in ethnic minority groups. Urbanicity was associated with a higher score on the general factor. Men presented with more negative and less depressive symptoms than women. Early age-at-first-contact with psychiatric services was associated with higher scores on negative, disorganized, and manic symptom dimensions.
CONCLUSIONS
Our results suggest that the bifactor model of psychopathology holds across diagnostic categories of non-affective and affective psychosis at FEP, and demographic and context determinants map onto general and specific symptom dimensions. These findings have implications for tailoring symptom-specific treatments and inform research into the mood-psychosis spectrum.

Identifiants

pubmed: 30282569
pii: S0033291718002131
doi: 10.1017/S0033291718002131
pmc: PMC6518388
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1378-1391

Subventions

Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101272/Z/13/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008436/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P005748/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : EPA
ID : EP-C-13-022
Pays : United States

Références

J Pers Assess. 2016;98(3):223-37
pubmed: 26514921
Br J Psychiatry. 1996 Jul;169(1):58-63
pubmed: 8818369
Qual Life Res. 2007;16 Suppl 1:19-31
pubmed: 17479357
CNS Spectr. 2014 Dec;19 Suppl 1:38-52; quiz 35-7, 53
pubmed: 25403863
Schizophr Res. 2003 Sep 1;63(1-2):89-95
pubmed: 12892862
Am J Psychiatry. 1997 Dec;154(12):1641-7
pubmed: 9396940
Acta Psychiatr Scand Suppl. 2000;(407):58-62
pubmed: 11261642
Schizophr Res. 2001 Mar 1;47(2-3):141-7
pubmed: 11278131
Schizophr Res. 2001 Mar 1;47(2-3):223-32
pubmed: 11278139
Arch Gen Psychiatry. 2001 Jul;58(7):663-8
pubmed: 11448373
Psychol Med. 1999 May;29(3):607-12
pubmed: 10405081
Psychopathology. 2008;41(4):264-70
pubmed: 18441528
Schizophr Bull. 2013 Jul;39(4):884-95
pubmed: 22258881
Schizophr Bull. 2017 Mar 1;43(2):240-244
pubmed: 27421793
Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
Schizophr Res. 2012 May;137(1-3):246-50
pubmed: 22356801
Am J Psychiatry. 2017 Feb 1;174(2):143-153
pubmed: 27771972
Psychol Med. 2009 Dec;39(12):1943-55
pubmed: 19627645
J Abnorm Psychol. 2017 May;126(4):454-477
pubmed: 28333488
Schizophr Bull. 1992;18(2):319-32
pubmed: 1377834
Psychol Med. 1996 Jul;26(4):775-83
pubmed: 8817712
Schizophr Bull. 2012 Nov;38(6):1118-23
pubmed: 23015685
PLoS One. 2012;7(11):e50119
pubmed: 23185552
Psychol Med. 1991 Aug;21(3):565-75
pubmed: 1946845
Br J Psychiatry. 2003 Jan;182:71-6
pubmed: 12509322
Psychol Methods. 2016 Jun;21(2):137-50
pubmed: 26523435
J Clin Psychiatry. 2014 Sep;75(9):964-74
pubmed: 24813261
Nat Med. 2016 Nov;22(11):1214-1219
pubmed: 27783064
Eur Psychiatry. 2012 Aug;27(6):406-8
pubmed: 21616645
Annu Rev Clin Psychol. 2010;6:391-419
pubmed: 20192792
Am J Psychiatry. 2002 Apr;159(4):539-45
pubmed: 11925290
J Nerv Ment Dis. 1994 Nov;182(11):631-8
pubmed: 7964671
Soc Psychiatry Psychiatr Epidemiol. 2015 Oct;50(10):1481-8
pubmed: 25895686
Br J Psychiatry. 2005 May;186:364-6
pubmed: 15863738
Br J Psychiatry. 1987 Aug;151:145-51
pubmed: 3690102
Schizophr Res. 1999 Sep 29;39(2):153-8; discussion 163
pubmed: 10507527
Br J Psychiatry. 2011 Aug;199(2):151-5
pubmed: 21804150
World Psychiatry. 2017 Oct;16(3):227-235
pubmed: 28941101
Schizophr Bull. 1990;16(3):537-45
pubmed: 2287938
Br J Psychiatry. 2006 Oct;189:346-53
pubmed: 17012658
J Clin Psychiatry. 2009 Oct;70(10):1432-8
pubmed: 19538905
Eur Arch Psychiatry Clin Neurosci. 2001 Aug;251(4):193-8
pubmed: 11697584
Br J Psychiatry. 2016 Aug;209(2):107-13
pubmed: 26989099
Psychol Med. 2015 Oct;45(13):2757-69
pubmed: 25936425
J Psychopharmacol. 2016 Jun;30(6):495-553
pubmed: 26979387
Aust N Z J Psychiatry. 2008 Jan;42(1):74-82
pubmed: 18058447
Annu Rev Clin Psychol. 2017 May 8;13:49-71
pubmed: 28482691
Am J Psychiatry. 2005 Oct;162(10):1824-32
pubmed: 16199828
JAMA Psychiatry. 2018 Jan 1;75(1):36-46
pubmed: 29214289
Lancet. 2009 Jan 17;373(9659):234-9
pubmed: 19150704
Psychol Med. 2011 Oct;41(10):2121-9
pubmed: 21466750
Int J Methods Psychiatr Res. 2007;16 Suppl 1:S34-40
pubmed: 17623393
Schizophr Bull. 2017 Jan;43(1):133-141
pubmed: 27220965
Schizophr Bull. 2014 May;40(3):504-15
pubmed: 24567502
Schizophr Res. 2003 Apr 1;60(2-3):259-69
pubmed: 12591588
Acta Psychiatr Scand. 1997 Jan;95(1):32-9
pubmed: 9051158
Schizophr Res. 2004 Dec 1;71(2-3):405-16
pubmed: 15474912
Am J Psychiatry. 2017 Mar 1;174(3):216-229
pubmed: 27919182
Biol Psychiatry. 2017 Mar 15;81(6):e41-e42
pubmed: 28190427
Biol Psychiatry. 2017 Feb 15;81(4):325-335
pubmed: 27519822
Psychol Med. 1999 May;29(3):595-606
pubmed: 10405080
Lancet. 2014 May 10;383(9929):1677-1687
pubmed: 24315522
Psychol Med. 2014 Jan;44(1):37-50
pubmed: 23461899
Am J Psychiatry. 2003 Jan;160(1):4-12
pubmed: 12505793
Curr Psychiatry Rep. 2008 Jun;10(3):223-8
pubmed: 18652790
Nature. 2009 Aug 6;460(7256):748-52
pubmed: 19571811
Schizophr Res. 1996 Dec 15;22(3):233-9
pubmed: 9000320
PLoS One. 2017 Feb 6;12(2):e0171595
pubmed: 28166306
Am J Psychiatry. 1983 Dec;140(12):1571-4
pubmed: 6650685
JAMA Psychiatry. 2017 Dec 1;74(12):1206-1213
pubmed: 29049482
Hist Psychiatry. 1994 Mar;5(17 Pt 1):13-36
pubmed: 11639278
Schizophr Bull. 2012 Mar;38(2):209-14
pubmed: 21857009
Biol Psychiatry. 2017 Mar 15;81(6):484-494
pubmed: 27667698
Schizophr Res. 1992 Sep;7(3):225-31
pubmed: 1390401
Schizophr Res. 2004 Apr 1;67(2-3):207-12
pubmed: 14984879
BMJ Open. 2015 Sep 07;5(9):e007619
pubmed: 26346872
Schizophr Res. 2007 Sep;95(1-3):30-8
pubmed: 17669627
Br Med J (Clin Res Ed). 1987 Sep 19;295(6600):681-2
pubmed: 3117295
Soc Psychiatry Psychiatr Epidemiol. 2002 Oct;37(10):460-4
pubmed: 12242624
Am J Psychiatry. 2011 May;168(5):472-85
pubmed: 21406461
Bipolar Disord. 2015 May;17(3):235-47
pubmed: 25346322
Lancet. 2009 Aug 22;374(9690):635-45
pubmed: 19700006
Schizophr Bull. 2017 Sep 1;43(5):1070-1078
pubmed: 27872260
Br J Psychiatry. 2016 Nov;209(5):361-365
pubmed: 27802977
BMC Psychiatry. 2014 Mar 26;14:88
pubmed: 24670212
Schizophr Bull. 2010 Jul;36(4):655-64
pubmed: 20513653
Arch Gen Psychiatry. 1978 Jun;35(6):773-82
pubmed: 655775
Neuropsychiatr Dis Treat. 2008 Dec;4(6):1089-109
pubmed: 19337453
World Psychiatry. 2003 Oct;2(3):172-8
pubmed: 16946931

Auteurs

Diego Quattrone (D)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London,London SE5 8AF,UK.

Marta Di Forti (M)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London,London SE5 8AF,UK.

Charlotte Gayer-Anderson (C)

Department of Health Service and Population Research,Institute of Psychiatry, King's College London,De Crespigny Park, Denmark Hill, London SE5 8AF,UK.

Laura Ferraro (L)

Department of Experimental Biomedicine and Clinical Neuroscience,University of Palermo,Via G. La Loggia 1, 90129 Palermo,Italy.

Hannah E Jongsma (HE)

Department of Psychiatry,University of Cambridge,Herchel Smith Building for Brain & Mind Sciences, Forvie Site, Robinson Way, Cambridge, CB2 0SZ,UK.

Giada Tripoli (G)

Department of Psychosis Studies,Institute of Psychiatry, King's College London,De Crespigny Park, Denmark Hill, London SE5 8AF,UK.

Caterina La Cascia (C)

Department of Experimental Biomedicine and Clinical Neuroscience,University of Palermo,Via G. La Loggia 1, 90129 Palermo,Italy.

Daniele La Barbera (D)

Department of Experimental Biomedicine and Clinical Neuroscience,University of Palermo,Via G. La Loggia 1, 90129 Palermo,Italy.

Ilaria Tarricone (I)

Department of Medical and Surgical Science, Psychiatry Unit,Alma Mater Studiorum Università di Bologna,Viale Pepoli 5, 40126 Bologna,Italy.

Domenico Berardi (D)

Department of Medical and Surgical Science, Psychiatry Unit,Alma Mater Studiorum Università di Bologna,Viale Pepoli 5, 40126 Bologna,Italy.

Andrei Szöke (A)

INSERM, U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil,France.

Celso Arango (C)

Department of Child and Adolescent Psychiatry,Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense,IiSGM (CIBERSAM), C/Doctor Esquerdo 46, 28007 Madrid,Spain.

Antonio Lasalvia (A)

Section of Psychiatry,Azienda Ospedaliera Universitaria Integrata di Verona,Piazzale L.A. Scuro 10, 37134 Verona,Italy.

Andrea Tortelli (A)

Etablissement Public de Santé Maison Blanche, Paris 75020,France.

Pierre-Michel Llorca (PM)

Université Clermont Auvergne,EA 7280, Clermont-Ferrand 63000,France.

Lieuwe de Haan (L)

Department of Psychiatry, Early Psychosis Section,Academic Medical Centre, University of Amsterdam,Meibergdreef 5, 1105 AZ Amsterdam,The Netherlands.

Eva Velthorst (E)

Department of Psychiatry, Early Psychosis Section,Academic Medical Centre, University of Amsterdam,Meibergdreef 5, 1105 AZ Amsterdam,The Netherlands.

Julio Bobes (J)

Department of Medicine,Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM),C/Julián Clavería s/n, 33006 Oviedo,Spain.

Miguel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital clinic,Department of Medicine,University of Barcelona,IDIBAPS, CIBERSAM, Barcelona,Spain.

Julio Sanjuán (J)

Department of Psychiatry,School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM),C/Avda. Blasco Ibáñez 15, 46010 Valencia,Spain.

Jose Luis Santos (JL)

Department of Psychiatry,Servicio de Psiquiatría Hospital "Virgen de la Luz",C/Hermandad de Donantes de Sangre, 16002 Cuenca,Spain.

Manuel Arrojo (M)

Department of Psychiatry, Psychiatric Genetic Group,Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela,Spain.

Cristina Marta Del-Ben (CM)

Division of Psychiatry, Department of Neuroscience and Behaviour,Ribeirão Preto Medical School, University of São Paulo,São Paulo,Brazil.

Paulo Rossi Menezes (PR)

Department of Preventative Medicine,Faculdade de Medicina FMUSP, University of São Paulo,São Paulo,Brazil.

Jean-Paul Selten (JP)

Rivierduinen Institute for Mental Health Care,Sandifortdreef 19, 2333 ZZ Leiden,The Netherlands.

Peter B Jones (PB)

Department of Psychiatry,University of Cambridge,Herchel Smith Building for Brain & Mind Sciences, Forvie Site, Robinson Way, Cambridge, CB2 0SZ,UK.

James B Kirkbride (JB)

Psylife Group, Division of Psychiatry,University College London,6th Floor, Maple House, 149 Tottenham Court Road, London W1T 7NF,UK.

Alexander L Richards (AL)

Division of Psychological Medicine and Clinical Neurosciences,MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University,Cardiff CF24 4HQ,UK.

Michael C O'Donovan (MC)

Division of Psychological Medicine and Clinical Neurosciences,MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University,Cardiff CF24 4HQ,UK.

Pak C Sham (PC)

Department of Psychiatry,the University of Hong Kong,Hong Kong,China.

Evangelos Vassos (E)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London,London SE5 8AF,UK.

Bart Pf Rutten (BP)

Department of Psychiatry and Neuropsychology,School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre,P.O. Box 616, 6200 MD Maastricht,The Netherlands.

Jim van Os (J)

Department of Psychosis Studies,Institute of Psychiatry, King's College London,De Crespigny Park, Denmark Hill, London SE5 8AF,UK.

Craig Morgan (C)

National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London,UK.

Cathryn M Lewis (CM)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London,London SE5 8AF,UK.

Robin M Murray (RM)

National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London,UK.

Ulrich Reininghaus (U)

Department of Health Service and Population Research,Institute of Psychiatry, King's College London,De Crespigny Park, Denmark Hill, London SE5 8AF,UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH